AMGN logo

Amgen Inc. (AMGN)

$457.93

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AMGN

Market cap

$247.70B

EPS

17.24

P/E ratio

25.7

Price to sales

5.89

Dividend yield

2.201%

Beta

0.433008

Price on AMGN

Previous close

$462.32

Today's open

$455.52

Day's range

$453.03 - $463.49

52 week range

$312.39 - $483.99

Profile about AMGN

CEO

Robert A. Bradway

Employees

31500

Headquarters

Thousand Oaks, CA

Exchange

Nasdaq Global Select

Shares outstanding

540911490

Issue type

Common Stock

AMGN industries and sectors

Healthcare

Pharmaceuticals

News on AMGN

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Amgen Securities Litigation

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Amgen Securities Litigation: UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE AMGEN INC. SECURITIES LITIGATION       Civil Action No. 1:23-cv-02138 (JPC) (HJR) CLASS ACTION SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS THAT PURCHASED OR OTHERWISE ACQUIRED AMGEN INC. (“AMGEN” OR THE “COMPANY”) COMMON STOCK BETWEEN JULY 29, 2020 AND APRI.

news source

Business Wire • 2 hours ago

news preview

Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500

Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?

news source

24/7 Wall Street • a day ago

news preview

A New King of Dividend ETFs

The Schwab U.S. Dividend Equity ETF (SCHD) is now the largest dividend ETF in the U.S. As of mid-November 2026, the fund held $125 billion in assets under management. It combines rigorous fundamental screening with a low 0.06% expense ratio.

news source

ETF Trends • a day ago

news preview

Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness

Dow Jones biotech giant Amgen stock is trading in a buy zone following its recent breakout move amid the ongoing market weakness.

news source

Investors Business Daily • Nov 16, 2026

news preview

The Winners Inside SCHD - November 2026

The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.

news source

Seeking Alpha • Nov 17, 2026

news preview

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.

news source

The Motley Fool • Nov 13, 2026

news preview

Dividend Champion, Contender, And Challenger Highlights: Week Of November 15

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

news source

Seeking Alpha • Nov 13, 2026

news preview

Amgen's experimental Sjogren's drug meets late-stage trial goal

Amgen said on ‌Wednesday its ​experimental ​drug showed ⁠sustained ​reduction in ​disease activity in ​a ​late-stage study ‌of ⁠patients with Sjogren's ​disease, ​an ⁠autoimmune condition.

news source

Reuters • Nov 11, 2026

news preview

Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data

Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease.

news source

Investors Business Daily • Nov 11, 2026

news preview

Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears

Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic autoimmune disease in which the immune system mistakenly attacks the body's moisture-producing glands.

news source

Benzinga • Nov 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Amgen Inc.

Open an M1 investment account to buy and sell Amgen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AMGN on M1